HIT: The Heparin-Induced Clot

If you're like me, the first time you heard "the anticoagulant is causing clots" you thought it was a riddle. Heparin-Induced Thrombocytopenia is exactly that paradox — a drug given to prevent clotting that, in susceptible patients, creates an immune-mediated thrombotic catastrophe. On the anesthesiology oral boards, HIT is a high-yield scenario because the management is counterintuitive and the traps are severe: give platelets when the count is low, or reach for more heparin when the patient is clotting — and you've done serious harm.

HIT is most likely to come up in the context of cardiac surgery (where unfractionated heparin is used in large doses for bypass), vascular surgery, or a post-operative thrombocytopenia workup. Know the four T's and know your alternative anticoagulants before you walk into that exam.

The Core Logic

HIT is caused by antibodies against a complex of heparin and platelet factor 4 (PF4). These antibodies bind to the Fc receptors on platelets, causing massive platelet activation and aggregation — a pro-thrombotic state, not a bleeding state. Platelets are being consumed to make clots, which is why the platelet count falls. The paradox: the low platelet count is evidence of thrombosis risk, not bleeding risk.

The clinical result: arterial and venous thromboses — limb ischemia, stroke, DVT, PE. In the setting of cardiac surgery, bypass circuit clotting. The treatment: stop all heparin exposure (including heparin flushes) and transition to a direct thrombin inhibitor that does not cross-react with the HIT antibodies.

How the Examiner Tests This

Classic scenario: a patient is 8 days post-CABG, platelet count has dropped from 200k to 65k, and there's now a new deep vein thrombosis. The examiner asks what's on your differential and how you'll manage it. The key move: immediately use the 4T score to estimate HIT probability, stop all heparin products while you await confirmatory testing, and transition to argatroban or bivalirudin.

The CABG-specific probe: "This patient needs redo cardiac surgery — can you use heparin for bypass?" This is the hardest version. If HIT antibodies are still present (titers detectable, usually within 3 months), you cannot use heparin for bypass. Alternatives include bivalirudin for bypass (requires specific monitoring) or delaying surgery until antibodies clear if the situation is elective.

The Board Trap

The platelet transfusion trap: the platelet count is 55k and there's going to be a procedure. The reflex is to transfuse platelets. In HIT, transfusing platelets provides more substrate for the HIT antibodies to activate — you're adding fuel to the fire. The correct answer is never to give platelets in HIT unless there's life-threatening bleeding or an absolutely emergent invasive procedure where the bleeding risk exceeds the thrombosis risk.

The "switch to LMWH" trap: low-molecular-weight heparin (enoxaparin) cross-reacts with HIT antibodies at a rate of approximately 90%. Switching from unfractionated heparin to LMWH does not treat HIT — you've simply changed the heparin product. The transition must be to a non-heparin anticoagulant.

Lead-In Phrases

• "My concern is Heparin-Induced Thrombocytopenia. I will immediately calculate the 4T score — if the probability is intermediate or high, I will stop all heparin products, including heparin flushes, while I confirm the diagnosis."
• "I will transition to a direct thrombin inhibitor — argatroban for patients with normal hepatic function, bivalirudin if hepatic function is impaired — while the confirmatory PF4 antibody test is pending."
• "I will not give platelets to this patient despite the low platelet count — in HIT, the thrombosis risk from transfusing platelets far exceeds any bleeding benefit."
• "For this patient who needs cardiac surgery with bypass, I will consult hematology regarding bivalirudin-based anticoagulation for the circuit — heparin cannot be used if HIT antibodies are detectable."
• "LMWH is not an acceptable alternative — the cross-reactivity rate with HIT antibodies is approximately 90%, and switching to enoxaparin does not treat the underlying immune mechanism."

FAQs

What is the 4T score?

The 4T score is a clinical prediction tool: Thrombocytopenia (degree and timing), Timing of platelet fall (5-10 days after heparin exposure is classic), Thrombosis (new clot), and other causes of Thrombocytopenia (excluded). A score of 0-3 is low probability, 4-5 intermediate, 6-8 high. For intermediate or high probability, stop heparin and start an alternative anticoagulant without waiting for confirmatory lab testing — the lab test takes 24-48 hours, and the thrombotic risk is immediate.

When can heparin be used again in a patient with prior HIT?

HIT antibodies typically become undetectable within 3-6 months. If a patient with remote HIT history needs cardiac surgery and HIT antibodies are not detectable by testing, a brief re-exposure to heparin for bypass is generally considered acceptable — but this requires hematology consultation and careful monitoring. If antibodies are still detectable, heparin cannot be used.

How is HIT monitored during treatment with argatroban?

Argatroban is monitored with aPTT, targeting 1.5-3 times baseline. It's hepatically metabolized — dose reduction needed in liver disease. Important caveat: argatroban also prolongs the INR, which complicates transitioning to warfarin. When transitioning, the INR target is typically above 4 on argatroban before warfarin is considered therapeutic.

HIT is the scenario where the counterintuitive answer is the right answer: more anticoagulation, not less, and absolutely no platelets. Practice the 4T score and alternative anticoagulant logic in Boards Bot until the management sequence is second nature.